Meeting
2023 ASCO Annual Meeting
Impact of obesity on the risk of immune-related adverse events (irAEs) among patients receiving immune-checkpoint inhibitors (ICI) treatment: A retrospective cohort study.
Authors
Mohamed I. Elsaid
The Ohio State University College of Medicine, Columbus, OH
Mohamed I. Elsaid , Electra D. Paskett , Aditi Shendre , Ashish Manne , Lang Li
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Other IO-Related Topics
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 2660)
DOI
10.1200/JCO.2023.41.16_suppl.2660
Abstract #
2660
Poster Bd #
502
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Prognostic impact of immune-related adverse events on survival outcomes in metastatic gastrointestinal cancer: A single-institutional experience.
First Author: Olisaemeka Ogbue
Poster
2022 ASCO Annual Meeting
Association between body mass index and treatment efficacy with immune checkpoint inhibitor therapy: A retrospective study.
First Author: Hannah Wang
Poster
2022 ASCO Annual Meeting
Preexisting autoantibodies as predictor of immune-related adverse events for advanced solid tumors treated with immune checkpoint inhibitors.
First Author: Arthur Daban
Poster
2020 Gastrointestinal Cancers Symposium
Hepatic adverse events during treatment with immune checkpoint inhibitors (ICI) in cancer patients: A territory-wide patient cohort study.
First Author: Stephen Lam Chan